MarketPulse

Depression

3 articles
BenzingaBenzinga··Evette Mitkov

Enveric Surges 106% on Trump's Psychedelics Push, but Downtrend Lingers

$ENVB surges 106% after Trump orders federal acceleration of psychedelic treatment approvals and commits $50M to ibogaine research, though stock remains deeply depressed technically.
ENVBbiotechregulatory approval
GlobeNewswire Inc.GlobeNewswire Inc.··Nexalin Technology, Inc.

Nexalin's Brain Stimulation Tech Shows Promise for Teen Depression, Self-Injury

Nexalin's DIFS neurostimulation technology reduced self-injury and depression symptoms in female adolescents, per peer-reviewed study published in BMC Psychiatry.
NXLclinical trialneurostimulation
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

NRx Pharmaceuticals Names TMS Expert as Chief Medical Innovation Officer

NRx Pharmaceuticals appoints Prof. Joshua Brown, leading TMS researcher, as Chief Medical Innovation Officer to advance PTSD and depression treatments for veterans.
NRXPNRXPWclinical trialsFDA